drugset
drugset / Trial / NCT03182257

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

NCT03182257 ↗

Phase 1 Terminated 1 enrolled Ono Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with advanced solid tumors, and evaluate efficacy of ONO-7579 in patients with advanced solid tumors harboring NTRK gene fusions.

Timeline

Start
2017-07-12
Primary completion
2018-01-30
Completion
2018-01-30

Outcome

Outcome not reported

Stopped: “The study was stopped for commercial reasons. No safety issues were reported.”

Drugs

EvaluationDrugModalityDoseRoute
Subject ONO-7579 Small molecule — —

Indications

cancer